Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Engineering NK cell-based cancer treatments

Juliane Mietz, University Of Zurich, Zurich, Switzerland, comments on ongoing research to develop anti-cancer natural killer (NK) cell therapies. Chimeric antigen receptor (CAR)-NK cells were initially studied alongside CAR T-cell, where both were engineered with CD28 or a 4-1BB costimulatory domains, domains found in axicabtagene ciloleucel and tisagenlecleucel, to assess the clinical efficacy of CAR-NK cells. Further pre-clinical studies involving CAR-NK cells are additionally underway to enhance their cytotoxicity in patients. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.